Seroepidemiological Study of SARS-CoV-2 (COVID-19) Infection in Population Subgroups in the State of São Paulo
NCT ID: NCT04408014
Last Updated: 2024-02-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
18901 participants
OBSERVATIONAL
2020-06-01
2020-07-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Real-world Evidence Study of BNT162b2 mRNA Covid-19 Vaccine in Brazil
NCT05052307
Clinical Trial for Assessment of Anti-SARS-CoV-2 Serum for Early Treatment of COVID-19 Cases
NCT04834089
Antiviral Agents Against COVID-19 Infection
NCT04468087
Nitazoxanide Therapy for Patients With COVID-19 Pneumonia
NCT04561219
Clinical Study to Evaluate the Effects of Disulfiram in Patients With Moderate COVID-19
NCT04594343
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HC-USP
Home contacts of health professionals diagnosed with COVID-19 at the Hospital of Clínic of Medicine School of the University of São Paulo
Serological test
IgM and IgG for SARS-CoV-2
Nasopharyngeal Swab
PCR for SARS-CoV-2
Oropharyngeal Swab
PCR for SARS-CoV-2
CORAS
Refugees living in the city of São Paulo
Serological test
IgM and IgG for SARS-CoV-2
Nasopharyngeal Swab
PCR for SARS-CoV-2
Oropharyngeal Swab
PCR for SARS-CoV-2
Hemocenter
Blood Donors of the Pró-Sangue Hemocenter Foundation of São Paulo
Serological test
IgM and IgG for SARS-CoV-2
CPP - Butantan Penitentiary Progression Center
Participants of the CPP - Butantan Penitentiary Progression Center
Serological test
IgM and IgG for SARS-CoV-2
Nasopharyngeal Swab
PCR for SARS-CoV-2
Oropharyngeal Swab
PCR for SARS-CoV-2
CHSP - Penitentiary System Hospital Center
Participants of the CHSP - Penitentiary System Hospital Center
Serological test
IgM and IgG for SARS-CoV-2
Nasopharyngeal Swab
PCR for SARS-CoV-2
Oropharyngeal Swab
PCR for SARS-CoV-2
SABE (Health, Wellness and Aging)
Participants of the SABE Project (Health, Wellness and Aging)
Serological test
IgM and IgG for SARS-CoV-2
Nasopharyngeal Swab
PCR for SARS-CoV-2
Oropharyngeal Swab
PCR for SARS-CoV-2
ILPI - Long-Term Care Institution for the Elderly
Residents of the Long-Term Care Institution for the Elderly of Botucatu
Serological test
IgM and IgG for SARS-CoV-2
Nasopharyngeal Swab
PCR for SARS-CoV-2
Oropharyngeal Swab
PCR for SARS-CoV-2
ICR-USP - Children's Institute of HCFMUSP
Home contacts of children and adolescents diagnosed with COVID-19, attended at the Children's Institute of HCFMUSP
Serological test
IgM and IgG for SARS-CoV-2
Nasopharyngeal Swab
PCR for SARS-CoV-2
Oropharyngeal Swab
PCR for SARS-CoV-2
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Serological test
IgM and IgG for SARS-CoV-2
Nasopharyngeal Swab
PCR for SARS-CoV-2
Oropharyngeal Swab
PCR for SARS-CoV-2
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
6 Months
100 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Butantan Institute
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alexander R Precioso, MD, PhD
Role: STUDY_CHAIR
Instituto butantan
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Avenida Vital Brasil 1500
São Paulo, , Brazil
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
COVID-19-Epi-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.